Navigation

Service-Menü

Hauptmenü



Bereichsmenü

Autoren mit:

WGL Logo

PsychAuthors

Literaturliste von Prof. Dr. rer. nat. Boris Quednow

letzte Aktualisierung: 29.09.2019

Dornbierer, D. A., Kometer, M., Von Rotz, R., Studerus, E., Gertsch, J., Gachet, M. S., Vollenweider, F. X., Seifritz, E., Bosch, O. G. & Quednow, B. B. (2019). Effects of gamma-hydroxybutyrate on neurophysiological correlates of performance and conflict monitoring. European Neuropsychopharmacology, 29(4), 539-548.

Hirsiger, S., Hänggi, J., Germann, J., Vonmoos, M., Preller, K. H., Engeli, E. J. E., Kirschner, M., Reinhard, C., Hulka, L. M., Baumgartner, M. R., Chakravarty, M. M., Seifritz, E., Herdener, M. & Quednow, B. B. (2019). Longitudinal changes in cocaine intake and cognition are linked to cortical thickness adaptations in cocaine users. NeuroImage: Clinical, 21, No. 101652.

Kroll, S. L., Williams, D. P., Thoma, M., Staib, M., Binz, T. M., Baumgartner, M. R., Kirschbaum, C., Thayer, J. F. & Quednow, B. B. (2019). Non-medical prescription opioid users exhibit dysfunctional physiological stress responses to social rejection. Psychoneuroendocrinology, 100, 264-275.

Schote, A. B., Jäger, K., Kroll, S. L., Vonmoos, M., Hulka, L. M., Preller, K. H., Meyer, J., Grünblatt, E. & Quednow, B. B. (2019). Glucocorticoid receptor gene variants and lower expression of NR3C1 are associated with cocaine use. Addiction Biology, 24(4), 730-742.

Vonmoos, M., Eisenegger, C., Bosch, O. G., Preller, K. H., Hulka, L. M., Baumgartner, M., Seifritz, E. & Quednow, B. B. (2019). Improvement of emotional empathy and cluster B personality disorder symptoms associated with decreased cocaine use severity. Frontiers in Psychiatry, 10, No. 213.

Bosch, O. G., Esposito, F., Dornbierer, D., von Rotz, R., Kraehenmann, R., Staempfli, P., Quednow, B. B. & Seifritz, E. (2018). Prohedonic properties of gamma-hydroxybutyrate are associated with changes in limbic resting-state functional connectivity. Human Psychopharmacology: Clinical and Experimental, 33(6), No. e2679.

Kirschner, M., Sladky, R., Haugg, A., Stämpfli, P., Jehli, E., Hodel, M., Engeli, E., Hösli, S., Baumgartner, M. R., Sulzer, J., Huys, Q. J. M., Seifritz, E., Quednow, B. B., Scharnowski, F. & Herdener, M. (2018). Self-regulation of the dopaminergic reward circuit in cocaine users with mental imagery and neurofeedback. EBioMedicine, 37, 489-498.

Kroll, S. L., Nikolic, E., Bieri, F., Soyka, M., Baumgartner, M. R. & Quednow, B. B. (2018). Cognitive and socio-cognitive functioning of chronic non-medical prescription opioid users. Psychopharmacology, 235(12), 3451-3464.

Kroll, S. L., Wunderli, M. D., Vonmoos, M., Hulka, L. M., Preller, K. H., Bosch, O. G., Baumgartner, M. R. & Quednow, B. B. (2018). Socio-cognitive functioning in stimulant polysubstance users. Drug and Alcohol Dependence, 190, 94-103.

Nagowski, N. K., Kirsch, P. K., Kübler, A. K. & Quednow, B. B. K. (2018). Stellungnahme der Sprechergruppe Biologische Psychologie und Neuropsychologie. Kommentar zu Meiser, T. et al. (2018). Positionspapier zur Rolle der Psychologischen Methodenlehre in Forschung und Lehre. Psychologische Rundschau, 69(4), 334-335.

Roberts, C. A., Quednow, B. B., Montgomery, C. & Parrott, A. C. (2018). MDMA and brain activity during neurocognitive performance: An overview of neuroimaging studies with abstinent 'ecstasy' users. Neuroscience and Biobehavioral Reviews, 84, 470-482.

Schleim, S. & Quednow, B. B. (2018). How realistic are the scientific assumptions of the neuroenhancement debate? Assessing the pharmacological optimism and neuroenhancement prevalence hypotheses. Frontiers in Pharmacology, 9, No. 3.

Weber, S. C., Kahnt, T., Quednow, B. B. & Tobler, P. N. (2018). Frontostriatal pathways gate processing of behaviorally relevant reward dimensions. PLoS Biology, 16(10), No. e2005722.

Khemka, S., Tzovara, A., Gerster, S., Quednow, B. B. & Bach, D. R. (2017). Modeling startle eyeblink electromyogram to assess fear learning. Psychophysiology, 54(2), 204-214.

Quednow, B. B., Hulka, L. M., Preller, K. H., Baumgartner, M. R., Eisenegger, C. & Vonmoos, M. (2017). Stable self-serving personality traits in recreational and dependent cocaine users. PLoS ONE, 12(3), No. e0172853.

Bermeitinger, C., Kaup, B., Kiesel, A., Koch, I., Kunde, W., Müsseler, J., Oberfeld-Twistel, D., Strobach, T., Ulrich, R., Liesefeld, H. R., Schütz-Bosbach, S., Müller, Hermann, J., Abele-Brehm, A., Gollwitzer, M., Daum, M. M., Eckstein, K., Schmiedek, F., Schuhrke, B., Allesch, C. G., Allolio-Näcke, L., Morgenroth, O., Wolfradt, U., Lüdmann, M., Rief, W. & Ohly, S. (2016). Positionspapier zur Lage der Allgemeinen Psychologie. Psychologische Rundschau, 67(3), 175-207.

Havranek, M. M., Bolliger, B., Roos, S., Pryce, C. R., Quednow, B. B. & Seifritz, E. (2016). Uncontrollable and unpredictable stress interacts with subclinical depression and anxiety scores in determining anxiety response. Stress, 19(1), 53-62.

Kroll, S. L., Herdener, M. & Quednow, B.B. (2016). Nicht medizinischer Gebrauch von Opiatanalgetika. Verbreitung, kognitive Folgen und Behandlung. Nervenheilkunde, 35(11), 779-783.

Tobler, P. N., Preller, K. H., Campbell-Meiklejohn, D. K., Kirschner, M., Kraehenmann, R., Stämpfli, P., Herdener, M., Seifritz, E. & Quednow, B. B. (2016). Shared neural basis of social and non-social reward deficits in chronic cocaine users. Social Cognitive and Affective Neuroscience, 11(6), 1017-1025.

Vonmoos, M., Schütz, C. G. & Quednow, B. B. (2016). Kognitive und sozial-kognitive Folgen des Kokainkonsums. Suchtmedizin, 18(4), 207-212.

Weber, S. C., Beck-Schimmer, B., Kajdi, M.-E., Müller, D., Tobler, P. N. & Quednow, B.B. (2016). Dopamine D2/3-and mu-opioid receptor antagonists reduce cue-induced responding and reward impulsivity in humans. Translational Psychiatry, 6, No. e850.

Wittwer, A., Hulka, L. M., Heinimann, H. R., Vonmoos, M. & Quednow, B. B. (2016). Risky decisions in a lottery task are associated with an increase of cocaine use. Frontiers in Psychology (Online Journal), 7, No. 640.

Wunderli, M. D., Vonmoos, M., Niedecker, S. M., Hulka, L. M., Preller, K. H., Baumgartner, M. R., Kraemer, T., Seifritz, E., Schaub, M. P., Eich-Höchli, D. & Quednow, B. B. (2016). Cognitive and emotional impairments in adults with attention-deficit/hyperactivity disorder and cocaine use. Drug and Alcohol Dependence, 163, 92-99.

Bosch, O. G., Eisenegger, C., Gertsch, J., von Rotz, R., Dornbierer, D., Gachet, M. S., Heinrichs, M., Wetter, T. C., Seifritz, E. & Quednow, B. B. (2015). Gamma-hydroxybutyrate enhances mood and prosocial behavior without affecting plasma oxytocin and testosterone. Psychoneuroendocrinology, 62, 1-10.

Hulka, L. M., Vonmoos, M., Preller, K. H., Baumgartner, M. R., Seifritz, E., Gamma, A. & Quednow, B.B. (2015). Changes in cocaine consumption are associated with fluctuations in self-reported impulsivity and gambling decision-making. Psychological Medicine, 45(14), 3097-3110.

Maier, L. J., Wunderli, M. D., Vonmoos, M., Römmelt, A. T., Baumgartner, M. R., Seifritz, E., Schaub, M. P. & Quednow, B. B. (2015). Pharmacological cognitive enhancement in healthy individuals: A compensation for cognitive deficits or a question of personality? PLoS ONE, 10(6), No. e0129805.

Schaub, M. P., Maier, L. J., Wenger, A., Haug, S., Stark, L., Berg, O., Beck, T. & Quednow, B. B. (2015). Evaluating the efficacy of a web-based self-help intervention with and without chat counseling in reducing the cocaine use of problematic cocaine users: the study protocol of a pragmatic three-arm randomized controlled trial. BMC Psychiatry (Online Journal).

Colzato, L. S., Sellaro, R., Hulka, L. M., Quednow, B. B. & Hommel, B. (2014). Cognitive control predicted by color vision, and vice versa. Neuropsychologia, 62, 55-59.

Doerig, N., Schlumpf, Y., Spinelli, S., Späti, J., Brakowski, J., Quednow, B. B., Seifritz, E. & Grosse Holtforth, M. (2014). Neural representation and clinically relevant moderators of individualised self-criticism in healthy subjects. Social Cognitive and Affective Neuroscience, 9(9), 1333-1340.

Easton, A. C., Lourdusamy, A., Desrivieres, S., Schumann, G., Fernandes, C., Mueller, C. P., Havranek, M., Quednow, B.B., Mizuno, K., Giese, K. P., Solati, J., Golub, Y., Moll, G. H., Clarke, T.-K., Vallada, H., Laranjeira, R., Moessner, R. & Kornhuber, J. (2014). alpha CaMKII controls the establishment of cocaine's reinforcing effects in mice and humans. Translational Psychiatry.

Hulka, L. M., Preller, K. H., Vonmoos, M., Jenni, D., Seifritz, E., Quednow, B.B., Eisenegger, C., Bendrick, K. & Baumgartner, M. R. (2014). Altered social and non-social decision-making in recreational and dependent cocaine users. Psychological Medicine, 44(5), 1015-1028.

Hulka, L. M., Treyer, V., Scheidegger, M., Preller, K. H., Vonmoos, M., Johyem, A., Baumgartner, M. R., Ametamey, S., Buck, A., Seifritz, E. & Quednow, B. B. (2014). Smoking but not cocaine use is associated with lower cerebral metabotropic glutamate receptor 5 density in humans. Mol Psychiatry, 19(5), 625-632.

Hysek, C. M., Schmid, Y., Simmler, L. D., Liechti, M. E., Domes, G., Heinrichs, M., Eisenegger, C., Preller, K. H. & Quednow, B. B. (2014). MDMA enhances emotional empathy and prosocial behavior. Social Cognitive and Affective Neuroscience, 9(11), 1645-1652.

Madry, M.M., Steuer, A. E., Vonmoos, M., Quednow, B.B., Baumgartner, M. R. & Kraemer, T. (2014). Retrospective monitoring of long-term recreational or dependent cocaine use in toenail clippings/scrapings as an alternative to hair. Bioanalysis, 6(23), 3183-3196.

Preller, K. H., Herdener, M., Schilbach, L., Stämpfli, P., Hulka, L. M., Vonmoos, M., Ingold, N., Vogeley, K., Tobler, P. N., Seifritz, E. & Quednow, B. B. (2014). Functional changes of the reward system underlie blunted response to social gaze in cocaine users. Proceedings of the National Academy of Sciences of the United States of America, 111(7), 2842-2847.

Preller, K. H., Hulka, L. M., Vonmoos, M., Jenni, D., Baumgartner, M. R., Seifritz, E., Dziobek, I. & Quednow, B. B. (2014). Impaired emotional empathy and related social network deficits in cocaine users. Addict Biol, 19(3), 452-466.

Quednow, B. B., Brzózka, M. & Rossner, M. J. (2014). Transcription factor 4 (TCF4) and schizophrenia: Integrating the animal and the human perspective. Cellular and Molecular Life Sciences, 71(15), 2815-2835.

Schmid, Y., Hysek, C. M., Simmler, L. D., Crockett, M. J., Quednow, B.B. & Liechti, M. E. (2014). Differential effects of MDMA and methylphenidate on social cognition. J Psychopharmacol, 28(9), 847-856.

Vonmoos, M., Hulka, L. M., Preller, K. H., Minder, F., Baumgartner, M. R. & Quednow, B. B. (2014). Cognitive impairment in cocaine users is drug-induced but partially reversible: evidence from a longitudinal study. Neuropsychopharmacology, 39(9), 2200-2210.

Bosch, O. B., Wagner, M., Jessen, F., Kühn, K. U., Joe, A., Seifritz, E., Maier, W., Biersack, H. J. & Quednow, B. B. (2013). Verbal memory deficits are correlated with prefrontal hypometabolism in 18FDG PET of recreational MDMA users. PLoS One, 8, e61234.

Hulka, L. M., Preller, K. H., Vonmoos, M., Broicher, S. D. & Quednow, B. B. (2013). Cocaine users manifest impaired prosodic and cross-modal emotion processing. Front Psychiatry, 4, 98.

Hulka, L. M., Wagner, M., Preller, K. H., Jenni, D. & Quednow, B. B. (2013). Blue-yellow color vision impairment and cognitive deficits in occasional and dependent stimulant users. Int J Neuropsychopharmacol, 16(3), 535-547.

Petrovsky, N., Ettinger, U., Kessler, H., Mössner, R., Wolfsgruber, S., Dahmen, N., Maier, W., Wagner, M. & Quednow, B. B. (2013). The effect of nicotine on sensorimotor gating is modulated by a CHRNA3 polymorphism. Psychopharmacology, 229(1), 31-40.

Petrovsky, N., Ettinger, U., Quednow, B. B., Landsberg, M. W., Drees, J., Lennertz, L., Frommann, I., Heilmann, K., Sträter, B., Kessler, H., Dahmen, N., Mössner, R., Maier, W. & Wagner, M. (2013). Nicotine enhances antisaccade performance in schizophrenia patients and healthy controls. International Journal of Neuropsychopharmacology, 16(7), 1473-1481.

Pfaff, M., Seidl, A., Angst, K., Ramseier, F., Seifritz, E., Quednow, B. B. & Böker, H. (2013). Elektrokonvulsionstherapie als Ultima Ratio in der Behandlung der Depression? Behandlungsleitlinien und Zuweisungspraxis. Psychiatrische Praxis, 40, 385-390.

Preller, K. H., Ingold, N., Vonmoos, M., Hulka, L. M., Jenni, D., Baumgartner, M. R., Vollenweider, F. X. & Quednow, B. B. (2013). Increased sensorimotor gating in recreational and dependent cocaine users is modulated by craving and ADHD symptoms. Biol Psychiatry, 73(3), 225-234.

Preller, K. H., Wagner, M., Sulzbach, C., Hoenig, K., Neubauer, J., Franke, P. E., Petrovsky, N., Frommann, I., Rehme, A. K. & Quednow, B. B. (2013). Sustained incentive value of heroin-related cues in short- and long-term abstinent heroin users. Eur Neuropsychopharmacol, 23(10), 1270-1279.

Quednow, B. B. (2013). Kokain und das Ego: Soziale Kognition bei Kokainkonsumenten. SuchtMagazin, 3, 28-32.

Quednow, B. B. (2013). Soziale Kognition und Interaktion bei Kokainkonsumenten: Substanzinduzierte Beeinträchtigungen können Therapie erschweren. InFo Neurologie & Psychiatrie, 11(5), 15-18.

Vonmoos, M., Hulka, L. M., Preller, K. H., Jenni, D., Baumgartner, M. R., Stohler, R., Bolla, K. & Quednow, B. B. (2013). Cognitive dysfunctions in recreational and dependent cocaine users: The role of ADHD, craving, and early age of onset. Br J Psychiatry, 203(1), 35-43.

Vonmoos, M., Hulka, L. M., Preller, K. H., Jenni, D., Schulz, C., Baumgartner, M. R. & Quednow, B. B. (2013). Differences in self-reported and behavioral measures of impulsivity in recreational and dependent cocaine users. Drug and Alcohol Dependence, 133(1), 61-70.

Bosch, O. B., Quednow, B.B., Seifritz, E. & Wetter, T. C. (2012). Reconsidering GHB: orphan drug or new model antidepressant? J Psychopharmacol, 26(5), 618-628.

Lennertz, L., Quednow, B.B., Schuhmacher, A., Petrovsky, N., Frommann, I., Schulze-Rauschenbach, S., Landsberg, M. W., Steinbrecher, A., Pukrop, R., Klosterkötter, J., Franke, P., Wölwer, W., Gaebel, W., Häfner, H., Maier, W., Wagner, M. & Mössner, R. (2012). The functional coding variant Asn107Ile of the neuropeptide S receptor gene (NPSR1) is associated with schizophrenia and modulates verbal memory and acoustic startle response. The International Journal of Neuropsychopharmacology, 15(9), 1205-1215.

Mössner, R., Schuhmacher, A., Wagner, M., Lennertz, L., Steinbrecher, A., Quednow, B.B., Rujescu, D., Rietschel, M. & Maier, W. (2012). The schizophrenia risk gene ZNF804A influences the antipsychotic response of positive schizophrenia symptoms. Eur Arch Psychiatry Clin Neurosci, 262(3), 193-197.

Petrovsky, N., Ettinger, U., Quednow, B. B., Walter, H., Schnell, K., Kessler, H., Mössner, R., Maier, W. & Wagner, M. (2012). Nicotine differentially modulates antisaccade performance in healthy male non-smoking volunteers stratified for low and high accuracy. Psychopharmacology, 221, 27-38.

Quednow, B.B., Kometer, M., Geyer, M. A. & Vollenweider, F. X. (2012). Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology, 37(3), 630-640.

Quednow, B.B., Treyer, V., Hasler, F., Dörig, N., Wyss, M. T., Burger, C., Rentsch, K. M., Westera, G., Schubiger, P. A., Buck, A. & Vollenweider, F. X. (2012). Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography. NeuroImage, 59(4), 3922-3932.

Quednow, B. B. (2012). Schizophrenia risk polymorphisms in the TCF4 gene interact with smoking in the modulation of auditory sensory gating. Proceedings of the National Academy of Sciences of the United States of America, 109(16), 6271-6276.

Quednow, B. B. & Pintsov, O. (2012). Endophänotypen in der psychiatrischen Forschung - Brückenschlag zwischen Genetk und Psychopathologie? In H. Böker & E. Seifritz (Hrsg.), Psychotherapie und Neurowissenschaften. Integration, Kritik, Zukunftsaussichten (S. 216-233). Bern: Huber.

Schuhmacher, A., Becker, T., Rujescu, D., Quednow, B.B., Lennertz, L., Wagner, M., Benninghoff, J., Rietschel, M., Häfner, H., Franke, P., Wölwer, W., Gaebel, W., Maier, W. & Mössner, R. (2012). Investigation of Tryptophan hydroxylase 2 (TPH2) in schizophrenia and in the response to antipsychotics. J Psychiatr Res, 46(8), 1073-1080.

Völter, C., Riedel, M., Wöstmann, N., Aichert, D. S., Lobo, S., Costa, A., Schmechtig, A., Collier, D. A., Hartmann, A. M., Giegling, I., Möller, H.-J., Quednow, B. B., Rujescu, D., Kumari, V. & Ettinger, U. (2012). Sensorimotor gating and D-2 receptor signalling: Evidence from a molecular genetic approach. International Journal of Neuropsychopharmacology, 15(10), 1427-1440.

Lennertz, L., Quednow, B. B., Benninghoff, J., Wagner, M., Maier, W. & Mössner, R. (2011). Impact of TCF4 on the genetics of schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 261(Supplement 2), 161-165.

Quednow, B. B. (2011). Muss nur die Chemie stimmen? Verbesserung der Gehirnleistung durch Drogen und Neuropsychopharmaka. In F. Vogelsang & C. Hoppe (Hrsg.), Sollen wir den Menschen verbessern? Versprechungen und Perspektiven des Neuroenhancements (S. 57-75). Bonn: Evangelische Akademie im Rheinland.

Quednow, B. B., Ettinger, U., Mössner, R., Rujescu, D., Giegling, I., Collier, D. A., Schmechtig, A., Kühn, K.-U., Möller, H.-J., Maier, W., Wagner, M. & Kumari, V. (2011). The schizophrenia risk allele C of the TCF4 rs9960767 polymorphism disrupts sensorimotor gating in schizophrenia spectrum and healthy volunteers. Journal of Neuroscience, 31(18), 6684-6691.

Mössner, R., Schuhmacher, A., Wagner, M., Quednow, B. B., Frommann, I., Kühn, K.-U., Schwab, S. G., Rietschel, M., Falkai, P., Wölwer, W., Ruhrmann, S., Bechdolf, A., Gaebel, W., Klosterkötter, J. & Maier, W. (2010). DAOA/G72 predicts the progression of prodromal syndromes to first episode psychosis. European Archives of Psychiatry and Clinical Neuroscience, 260(3), 209-215.

Petrovsky, N., Quednow, B. B., Ettinger, U., Schmechtig, A., Mössner, R., Collier, D. A., Kühn, K.-U., Maier, W., Wagner, M. & Kumari, V. (2010). Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers. Neuropsychopharmacology, 35(7), 1429-1439.

Quednow, B.B. (2010). Tyrannische Neurobiologie und unterdrückte Kultur des psychotropen Erlebens. Zeitschrift für Kulturwissenschaften, 2, 79-84.

Quednow, B.B. (2010). Ethics of neuroenhancement: a phantom debate. BioSocieties, 5, 153-156.

Quednow, B. B. (2010). Neurophysiologie des Neuroenhancements: Möglichkeiten und Grenzen. SuchtMagazin, 2010(2), 19-26.

Quednow, B. B., Geyer, M. A. & Halberstadt, A. L. (2010). Serotonin and schizophrenia. In C. P. Müller & B. L. Jacobs (Eds.), Handbook of the behavioral neurobiology of serotonin, Vol. 21 (pp. 585-620). London: Academic Press.

Quednow, B. B., Wagner, M., Mössner, R., Maier, W. & Kühn, K.-U. (2010). Sensorimotor gating of schizophrenia patients depends on Catechol O-methyltransferase Val hoch 158Met polymorphism. Schizophrenia Bulletin, 36(2), 341-346.

Rehme, A. K., Frommann, I., Peters, S., Block, V., Bludau, J., Quednow, B. B., Maier, W., Schütz, C. & Wagner, M. (2010). Appetitive drug cue effects in former and active smokers. Addiction, 104(10), 1757-1764.

Hasler, F., Kuznetsova, O. F., Krasikova, R. N., Cservenyak, T., Quednow, B.B., Vollenweider, F. X., Ametamey, S. M. & Westera, G. (2009). GMP-compliant radiosynthesis of [super 18F]altanserin and human plasma metabolite studies. Applied Radiation and Isotopes, 67(4), 598-601.

Mössner, R., Schuhmacher, A., Kühn, K.-U., Cvetanovska, G., Rujescu, D., Zill, P., Quednow, B. B., Rietschel, M., Wölwer, W., Gaebel, W., Wagner, M. & Maier, W. (2009). Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenetics and Genomics, 19(1), 91-94.

Quednow, B. B., Schmechtig, A., Ettinger, U., Petrovsky, N., Collier, D. A., Vollenweider, F. X., Wagner, M. & Kumari, V. (2009). Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln genotype: A replication study. Biological Psychiatry, 66(6), 614-620.

Schuhmacher, A., Mössner, R., Quednow, B. B., Kühn, K.-U., Wagner, M., Cvetanovska, G., Rujescu, D., Zill, P., Möller, H.-J., Rietschel, M., Franke, P., Wölwer, W., Gaebel, W. & Maier, W. (2009). Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia. Pharmacogenetics and Genomics, 19(11), 843-851.

Csomor, P. A., Vollenweider, F. X., Nicolet, T., Yee, B. K., Feldon, J. & Quednow, B. B. (2008). On the influence of baseline startle reactivity on the indexation of prepulse inhibition. Behavioral Neuroscience, 122(4), 885-900.

Gertsch, J., Raduner, S., Tytgat, J., Peigneur, S., Quednow, B., Bilkei-Gorzo, A., Zimmer, A. & Altmann, K. H. (2008). Analgesic and neuropsychological effect of Echinacea N-alkylamides. Planta Medica, 74, PA302.

Maier, W., Mössner, R., Quednow, B.B., Wagner, M. & Hurlemann, R. (2008). From genes to psychosis and back: the role of the 5-HT2A receptor and prepulse inhibition in schizophrenia. Eur Arch Psychiatry Clin Neurosci, Supplement 5, 258, 40-43.

Maier, W., Mössner, R., Quednow, B. B., Wagner, M. & Hurlemann, R. (2008). From genes to psychoses and back: The role of the 5HT2alpha-receptor and prepulse inhibition in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 258(Suppl. 5), 40-43.

Pfaff, M., Quednow, B. B., Brüne, M. & Juckel, G. (2008). Schizophrenie und Religiosität - Eine Vergleichsstudie zur Zeit der innerdeutschen Teilung. Psychiatrische Praxis, 35(5), 240-246.

Quednow, B. B. (2008). Defizite der sensomotorischen Filterleistung bei psychiatrischen Erkrankungen. Zeitschrift für Neuropsychologie, 19(3), 139-163.

Quednow, B. B., Csomor, P. A., Chmiel, J., Beck, T. & Vollenweider, F. X. (2008). Sensorimotor gating and attentional set-shifting are improved by the my-opioid receptor agonist morphine in healthy human volunteers. International Journal of Neuropsychopharmacology, 11(5), 655-669.

Quednow, B. B., Frommann, I., Berning, J., Kühn, K.-U., Maier, W. & Wagner, M. (2008). Impaired sensorimotor gating of the acoustic startle response in the prodrome of schizophrenia. Biological Psychiatry, 64(9), 766-773.

Quednow, B. B., Kühn, K.-U., Mössner, R., Schwab, S. G., Schuhmacher, A., Maier, W. & Wagner, M. (2008). Sensorimotor gating of schizophrenia patients is influenced by 5-HT sub 2A receptor polymorphisms. Biological Psychiatry, 64(5), 434-437.

Westheide, J., Quednow, B. B., Kuhn, K.-U., Hoppe, C., Cooper-Mahkorn, D., Hawellek, B., Eichler, P., Maier, W. & Wagner, M. (2008). Executive performance of depressed suicide attempters: The role of suicidal ideation. European Archives of Psychiatry and Clinical Neuroscience, 258(7), 414-421.

Quednow, B. B., Kühn, K.-U., Hoppe, C., Westheide, J., Maier, W., Daum, I. & Wagner, M. (2007). Elevated impulsivity and impaired decision-making cognition in heavy users of MDMA ("Ecstasy"). Psychopharmacology, 189(4), 517-530.

Vollenweider, F. X., Csomor, P. A., Knappe, B., Geyer, M. A. & Quednow, B. B. (2007). The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval. Neuropsychopharmacology, 32(9), 1876-1887.

Westheide, J., Wagner, M., Quednow, B. B., Hoppe, C., Cooper-Mahkorn, D., Strater, B., Maier, W. & Kuhn, K.-U. (2007). Neuropsychological performance in partly remitted unipolar depressive patients: Focus on executive functioning. European Archives of Psychiatry and Clinical Neuroscience, 257(7), 389-395.

Csomor, P. A., Yee, B. K., Quednow, B. B., Stadler, R. R., Feldon, J. & Vollenweider, F. X. (2006). The monotonic dependency of prepulse inhibition of the acoustic startle reflex on the intensity of the startle-eliciting stimulus. Behavioural Brain Research, 174(1), 143-150.

Quednow, B.B., Westheide, J., Kühn, K. U., Werner, P., Maier, W., Hawellek, B. & Wagner, M. (2006). Normal prepulse inhibition and habituation of acoustic startle response in suicidal depressive patients without psychotic symptoms. Journal of Affective Disorders, 92(2-3), 299-303.

Quednow, B. B., Jessen, F., Kühn, K.-U., Maier, W., Daum, I. & Wagner, M. (2006). Memory deficits in abstinent MDMA (ecstasy) users: Neuropsychological evidence of frontal dysfunction. Journal of Psychopharmacology, 20(3), 373-384.

Quednow, B. B., Kühn, K.-U., Beckmann, K., Westheide, J., Maier, W. & Wagner, M. (2006). Attenuation of the prepulse inhibition of the acoustic startle response within and between sessions. Biological Psychology, 71, 256-263.

Quednow, B. B., Wagner, M., Westheide, J., Beckmann, K., Bliesener, N., Maier, W. & Kühn, K.-U. (2006). Sensorimotor gating and habituation of the startle response in schizophrenic patients randomly treated with amisulpride or olanzapine. Biological Psychiatry, 59(6), 536-545.

Hoenig, K., Hochrein, A., Quednow, B. B., Maier, W. & Wagner, M. (2005). Impaired prepulse inhibition of acoustic startle in obsessive-compulsive disorder. Biological Psychiatry, 57(10), 1153-1158.

Kuhn, K. U., Quednow, B.B., Riedel, M., Krampe, O. & Maier, W. (2005). Safety and efficacy of citalopram in the treatment of depressive disorders. Psychopharmakotherapie, 12, 83-90.

Kühn, K.-U., Quednow, B. B., Riedel, M., Krampe, O. & Maier, W. (2005). Sicherheit und Effektivität von Citalopram in der Behandlung depressiver Erkrankungen. Psychopharmakotherapie, 12(3), 83-90.

Quednow, B. B. (2004). Folgen des Ecstasy-Konsums. Neurobiologische Grundlagen kognitiver Leistungsdefizite bei MDMA-Konsumenten. Dissertation, Universität, Fakultät für Psychologie, Bochum.

Wagner, M., Quednow, B.B., Westheide, J., Schlaepfer, T. E., Maier, W. & Kuhn, K. U. (2005). Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology, 30, 381-390.

Wagner, M., Quednow, B.B., Westheide, J., Schlaepfer, T., Maier, W. & Kühn, K. U. (2005). Cognitive improvement in schizophrenic patients by modern antipsychotics does not require a serotonergic mechanism: Randomized controlled trial of olanzapine versus amisulpride. Neuropsychopharmacology, 30, 381-390.

Bliesener, N., Yokusoglu, H., Quednow, B.B., Klingmüller, D. & Kühn, K.-U. (2004). Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: A case report. Pharmacopsychiatry, 37, 189-191.

Kühn, K.-U., Joe, A. Y., Meyer, K., Reichmann, K., Maier, W., Rao, M. L., Reinhardt, M. J., Biersack, H.-J. & Quednow, B.B. (2004). Neuroimaging and 5-HT2C receptor polymorphism: A HMPAO-SPECT study in healthy male probands using mCPP-challenge of the 5-HT2C receptor. Pharmacopsychiatry, 37, 286-291.

Kühn, K.-U., Quednow, B.B., Landen, H., Riedel, M. & Thiel, M. (2004). Lebensqualität und Therapieerfolg in der ambulanten Schizophrenie-Therapie mit Flupentixol: Eine Anwendungsbeobachtung. Fortschritte der Neurologie, Psychiatrie, 72(7), 397-403.

Quednow, B. B., Kühn, K.-U., Hoenig, K., Maier, W. & Wagner, M. (2004). Prepulse inhibition and habituation of acoustic startle response in male MDMA ('ecstasy') users, cannabis users, and healthy controls. Neuropsychopharmacology, 29(5), 982-990.

Quednow, B. B., Kühn, K.-U., Stelzenmueller, R., Hoenig, K., Maier, W. & Wagner, M. (2004). Effects of serotonergic and noradrenergic antidepressants on auditory startle response in patients with major depression. Psychopharmacology, 175, 399-406.

Kuhn, K.-U., Quednow, B. B., Thiel, M., Falkai, P., Maier, W. & Elger, C. E. (2003). Antidepressive treatment in patients with temporal lobe epilepsy and major depression: A prospective study with three different antidepressants. Epilepsy & Behavior, 4(6), 674-679.

Kühn, K. U., Quednow, B.B., Barkow, C., Heun, R., Linden, M. & Maier, W. (2002). Psychosoziale Beeinträchtigung bei Patienten mit depressiven Störungen in der Allgemeinarztpraxis. Nervenarzt, 73, 644-650.

Kühn, K. U., Quednow, B.B., Barkow, K., Heun, R., Linden, M. & Maier, W. (2002). Chronifizierung und psychosoziale Behinderung durch depressive Erkrankungen bei Patienten in der Allgemeinarztpraxis im Einjahresverlauf. Ergebnisse aus einer Studie der Weltgesundheitsorganisation. Der Nervenarzt, 73(7), 644-650.

Kühn, K.-U., Quednow, B.B., Bagli, M., Meyer, K., Feuchtl, A., Westheide, J., Frahnert, C., Maier, W. & Rao, M. L. (2002). Allelic variants of the serotonin(2C) receptor and neuroendocrinological responses to the serotonin(2C) receptor agonist m-chlorophenylpiperazine in healthy male volunteers. Pharmacopsychiatry, 35, 226-230.



weiterführende Informationen

Weitere Informationen

Möchten Sie auch in die Datenbank aufgenommen werden oder haben Sie Änderungswünsche an Ihrem vorhandenen Profil; bitte nehmen Sie zu uns Kontakt auf.

Dr. Gabriel Schui
Leibniz-Institut für Psychologie (ZPID)
Universitätsring 15,
54296 Trier
Folgen Sie uns auf Twitter

Kontakt und Funktionen

URL der Seite: https://psychauthors.de/psychauthors/index.php?wahl=forschung&uwahl=psychauthors&uuwahl=p00873BQ_pub